Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.
Deshycka R, Sudaryo V, Huang NJ, Xie Y, Smeding LY, Choi MK, Ploegh HL, Lodish HF, Pishesha N.
Deshycka R, et al. Among authors: ploegh hl.
PLoS One. 2021 Nov 3;16(11):e0259353. doi: 10.1371/journal.pone.0259353. eCollection 2021.
PLoS One. 2021.
PMID: 34731223
Free PMC article.
Antibody and RNAi-based PCSK9 inhibitor treatments lower cholesterol and prevent cardiovascular incidents in patients, but their high-cost hampers market penetration. We sought to develop a safe, long-term and one-time solution to treat hyperlipidemia. We created a cDNA en …
Antibody and RNAi-based PCSK9 inhibitor treatments lower cholesterol and prevent cardiovascular incidents in patients, but their high-cost h …